DoW Ovarian Cancer, Clinical Trial Award
Funds clinical trials of ovarian cancer drugs, biologics, devices or guidance, from small pilots to large efficacy studies.
A promising ovarian cancer idea still has to prove itself in people, and it has to do so at whatever scale honestly matches the evidence behind it so far. This award funds that step directly.
What is funded is the rapid implementation of clinical trials with the potential to meaningfully change how ovarian cancer is treated or managed. Trials can evaluate promising new products, pharmacologic age…
Clinical trials of promising ovarian cancer products — pharmacologic agents, devices, clinical guidance or emerging approaches and technologies — ranging from small proof-of-concept studies (pilot, first-in-human, phase 0) to large-scale efficacy trials in relevant patient populations.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up